Jump to content
Advertisement

All Activity

This stream auto-updates     

  1. Yesterday
  2. Episode #9 Shifting from “having IBS” to “have had IBS” is the goal of Dr. Jennifer Franklin (Ph.D., MACP). In this podcast, Dr. Jennifer Franklin (Ph.D., MACP) and I spoke about her unique perspective on how therapy can help people with functional GI disorders. Relationship healing plays a large role in dealing with IBS and this is often something that is addressed by therapy. The relationship that you have with your IBS is something that is worth exploring and as Dr. Franklin (Ph.D., MACP) refers to, as “shifting your patterns”. Dr. Franklin wants patients to feel hopeful and she created the website DontHateYourGuts.com to help patients to be inspired to seek healing and not just symptom management. Dr. Franklin (Ph.D., MACP) offers psychotherapy for individuals, couples and families that she sees on a regular basis as well new patients that she might see for an individual consultation. She is currently working on a webinar series and is involved in writing a book as well as some YouTube videos. https://www.ibspatient.org/podcasts/ or https://www.podbean.com/ew/pb-7gjfd-c78472 or Say "Play the latest podcast from IBS Chat" from Apple iTunes or Google Play
  3. Jeffrey Roberts

    IBS Clear

    I have never seen any research involving IBS Clear or any of its ingredients other than peppermint. In my opinion, you might be more confident with peppermint capsules such as in IBgard to try and relieve IBS symptoms than with IBS Clear.
  4. School's strict loo roll rules leaves child 'too scared to go to the toilet' WalesOnlineView the full article
  5. jane5000

    IBS Clear

    Has anyone tried the product IBS clear? Any results?
  6. Sometimes nausea and a lack of hunger could be due to another functional gastrointestinal disorder (FGiD) further up in your digestive system rather than just IBS. FGiD's tend to cluster. If you also have a burning or gnawing feeling in your stomach then you might benefit from an acid blocker called a PPI. Something to speak to your doctor about.
  7. Jeffrey Roberts

    Always worried it’s maybe worse than IBS

    Not saying what your feeling is because you are starting a new job, though starting a new job can be incredibly stressful and I am affected exactly how you have described it when I start a new job. While I really hope you don't have anything more serious going on, it does sound like an IBS vicious cycle. If someone diagnosed you in 2011 than you can feel pretty confident that that's still the diagnosis and you are just going through a bad flare. Also, if the SIBO antibiotic treatment worked, you could do that again to try and see if that helps.
  8. RT @FODMAPLife: Join me as I host @KateScarlata_RD for a Facebook Live broadcast, “Constipation Remedies.” Tues., Nov 19 at 1 p.m. EST. Sponsored by @OrgranGF Join us HERE: http://bit.ly/ConstipationRemedy #lowfodmap #fodmap #guthealth #dietitian #digestivehealth #guthealth #constipation https://t.co/y0UigAYf4v (Feed generated with FetchRSS) View the full article
  9. RT @MsKymLang: A thought-provoking article on IBS and stigma by dietitian @KateScarlata_RD https://blog.katescarlata.com/2019/11/13/ibs-stigma/ #IBS (Feed generated with FetchRSS) View the full article
  10. Last week
  11. I have been trying more so lately to notice patterns in how I feel and my IBS. I have noticed that it seems every few months I go through a week or so of having no appetite/feeling nauseous and it seems to be when I am constipated. I regularly take a fiber supplement and try my best to have a high fiber cereal on the daily but when I am not hungry/feel nauseous the last thing I want to do is eat. I am wondering if anyone else experiences these types of symptoms and what you have found to help? I am due to see my primary care doctor next month and will discuss this with her as well, and seeing the gastroenterologist in January. I always get so anxious when I don’t feel well because this past winter I had a stomach infection which impacted my appetite and caused nausea. I get nervous it has come back, but I hope it’s more just ibs symptoms flaring up. Thanks everyone.
  12. Hi, I was diagnosed with IBS and SIBO back in 2011. 2 months back I went through a 14 day SIBO antibiotic treatment. Yesterday I started a new job and either I am having an attack like none other or something else is up. Does anyone ever experience the following? A nagging sensation that doesn’t hurt but feels like your lower left abdomen is full or cramped. Random stools of all types and sometimes multicolored? I have scheduled a colonoscopy because I’m a wreck worried that this maybe Stomach cancer or something horrible. This worry doesn’t help IBS! Vicious Circle activate!
  13. Related Articles Use of Treatments for Irritable Bowel Syndrome and Patient Satisfaction, Based on IBS in America Survey. Gastroenterology. 2019 Nov 08;: Authors: Rangan V, Ballou S, Shin A, Camilleri M, Beth Israel Deaconess Medical Center GI Motility Working Group, Lembo A PMID: 31711922 [PubMed - as supplied by publisher] View the full article
  14. Related Articles Lactose and Fructo-oligosaccharides Increase Visceral Sensitivity in Mice via Glycation Processes, Increasing Mast Cell Density in Colonic Mucosa. Gastroenterology. 2019 Nov 08;: Authors: Kamphuis JBJ, Guiard B, Leveque M, Olier M, Jouanin I, Yvon S, Tondereau V, Rivière P, Guéraud F, Chevolleau S, Noguer-Meireles MH, Martin JF, Debrauwer L, Eutamène H, Theodorou V Abstract BACKGROUND AND AIMS: Irritable bowel syndrome (IBS) is characterized by abdominal pain, bloating, and erratic bowel habits. A diet low in fermentable oligo-, di-, mono-saccharides and polyols (FODMAPs) can reduce symptoms of IBS, possibly by reducing microbial fermentation products. We investigated whether ingestion of FODMAPs can induce IBS-like visceral hypersensitivity mediated by fermentation products of intestinal microbes in mice. METHODS: C57Bl/6 mice were gavaged with lactose, with or without the anti-glycation agent pyridoxamine, or saline (controls) daily for 3 weeks. A separate group of mice were fed a diet containing fructo-oligosaccharides, with or without pyridoxamine in drinking water, or a normal chow diet (controls) for 6 weeks. Feces were collected and analyzed by 16S rRNA gene sequencing and bacterial community analyses. Abdominal sensitivity was measured by electromyography and mechanical von Frey filament assays. Colon tissues were collected from some mice and analyzed by histology and immunofluorescence, to quantify mast cells and expression of advanced glycosylation end-product specific receptor (AGER). RESULTS: Mice gavaged with lactose or fed fructo-oligosaccharides had increased abdominal sensitivity compared with controls, associated with increased numbers of mast cells in colon and expression of the receptor for AGER in proximal colon epithelium. These effects were prevented by administration of pyridoxamine. Lactose and/or pyridoxamine did not induce significant alterations in the composition of the fecal microbiota. Mass spectrometric analysis of carbonyl compounds in fecal samples identified signatures associated with mice given lactose or fructo-oligosaccharides vs controls. CONCLUSION: We found that oral administration of lactose or fructo-oligosaccharides to mice increases abdominal sensitivity, associated with increased numbers of mast cells in colon and expression of AGER; these can be prevented with an anti-glycation agent. Lactose and/or pyridoxamine did not produce alterations in fecal microbiota of mice. Our findings indicate that preventing glycation reactions might reduce abdominal pain in patients with IBS with sensitivity to FODMAPs. PMID: 31711923 [PubMed - as supplied by publisher] View the full article
  15. Biofeedback for treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2019 Nov 12;2019(11): Authors: Goldenberg JZ, Brignall M, Hamilton M, Beardsley J, Batson RD, Hawrelak J, Lichtenstein B, Johnston BC Abstract BACKGROUND: Irritable bowel syndrome (IBS) is a prevalent condition that currently lacks highly effective therapies for its management. Biofeedback has been proposed as a therapy that may help individuals learn to exert conscious control over sympatho-vagal balance as an indirect method of symptom management. OBJECTIVES: Our primary objective was to assess the efficacy and safety of biofeedback-based interventions for IBS in adults and children. SEARCH METHODS: We searched the Cochrane Inflammatory Bowel Disease (IBD) Group Specialized Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, the Cumulative Index to Nursing and Allied Health Literature (CINAHL), and the Allied and Complementary Medicine Database (AMED) from inception to 24 July 2019. We also searched reference lists from published trials, trial registries, device manufacturers, conference proceedings, theses, and dissertations. SELECTION CRITERIA: We judged randomized controlled trials to be eligible for inclusion if they met the Association for Applied Psychophysiology and Biofeedback definition of biofeedback, and if they compared a biofeedback intervention to an active, sham, or no-treatment control for the management of IBS. DATA COLLECTION AND ANALYSIS: Two authors independently screened trials for inclusion, extracted data, and assessed risk of bias. Primary outcomes were IBS global or clinical improvement scores and overall quality of life measures. Secondary outcome measures were adverse events, assessments of stool frequency and consistency, changes in abdominal pain, depression, and anxiety. For dichotomous outcomes, we calculated the risk ratio (RR) and 95% confidence interval (CI). For continuous outcomes, we calculated the mean difference (MD) and 95% CI. We used GRADE criteria to assess the overall certainty of the evidence. MAIN RESULTS: We identified eight randomized trials with a total of 300 adult participants for our analysis. We did not identify any trials in children. Four trials assessed thermal biofeedback. One trial assessed rectosigmoidal biofeedback. Two trials assessed heart rate variability biofeedback. Two trials assessed electrocutaneous biofeedback. Comparators were: no treatment (symptom monitoring group; three studies), attention control (pseudomeditation; two studies), relaxation control (one study), counseling (two studies), hypnotherapy (one study), standard therapy (one study), and sham biofeedback (one study). We judged all trials to have a high or unclear risk of bias. Global/Clinical improvement The clinical benefit of biofeedback plus standard therapy compared to standard therapy alone was uncertain (RR 4.20, 95% CI 1.40 to 12.58; 1 study, 20 participants; very low-certainty evidence). The same study also compared biofeedback plus standard therapy to sham biofeedback plus standard therapy. The clinical benefit in the biofeedback group was uncertain (RR 2.33, 95% CI 1.13 to 4.80; 1 study, 20 participants; very low-certainty evidence). The clinical benefit of heart rate biofeedback compared to hypnotherapy was uncertain when measured with the IBS severity scoring system (IBS-SSS) (MD -58.80, 95% CI -109.11 to -8.49; 1 study, 61 participants; low-certainty evidence). Compared to counseling, the effect of heart rate biofeedback was unclear when measured with a composite symptom reduction score (MD 7.03, 95% CI -51.07 to 65.13; 1 study, 29 participants; low-certainty evidence) and when evaluated for clinical response (50% improvement) (RR 1.09, 95% CI 0.48 to 2.45; 1 study, 29 participants; low-certainty evidence). The clinical benefit of thermal biofeedback used in a multi-component psychological intervention (MCPI) compared to no treatment was uncertain when measured with a composite clinical symptom reduction score (MD 30.34, 95% CI 8.47 to 52.21; 3 studies, 101 participants; very low-certainty evidence), and when evaluated as clinical response (50% improvement) (RR 2.12, 95% CI 1.24 to 3.62; 3 studies, 101 participants; very low-certainty evidence). Compared to attention control, the effects of thermal biofeedback within an MCPI were unclear when measured with a composite clinical symptom reduction score (MD 4.02, 95% CI -21.41 to 29.45; 2 studies, 80 participants; very low-certainty evidence) and when evaluated as clinical response (50% improvement) (RR 1.10, 95% CI 0.72 to 1.69, 2 studies, 80 participants; very low-certainty evidence). Quality of life A single trial used overall quality of life as an outcome measure, and reported that both the biofeedback and cognitive therapy groups improved after treatment. The trial did not note any between-group differences, and did not report any outcome data. Adverse events Only one of the eight trials explicitly reported adverse events. This study reported no adverse events in either the biofeedback or cognitive therapy groups (RD 0.00, 95% CI -0.12 to 0.12; 29 participants; low-certainty evidence). AUTHORS' CONCLUSIONS: There is currently not enough evidence to assess whether biofeedback interventions are effective for controlling symptoms of IBS. Given the positive results reported in small trials to date, biofeedback deserves further study in people with IBS. Future research should include active control groups that use high provider-participant interaction, in an attempt to balance non-specific effects of interventions between groups, and report both commonly used outcome measures (e.g. IBS-SSS) and historical outcome measures (e.g. the composite primary symptom reduction (CPSR) score) to allow for meta-analysis with previous studies. Future studies should be explicit in their reporting of adverse events. PMID: 31713856 [PubMed - in process] View the full article
  16. Identification of Three Antimicrobials Activating Serotonin Receptor 4 in Colon Cells. ACS Synth Biol. 2019 Nov 12;: Authors: Yasi EA, Allen AA, Sugianto W, Peralta-Yahya P Abstract The serotonin receptor 4b (5-HTR4b) is expressed throughout the gastrointestinal tract, and its agonists are used in the treatment of irritable bowel syndrome with constipation (IBS-C). Today, there are no rapid assays for the identification of 5-HTR4b agonists. Here, we developed a luciferase-based 5-HTR4b assay capable of assessing one compound per second with a 38-fold dynamic range and nM limit of detection for serotonin. We used the assay to screen more than 1000 natural products and anti-infection agents and identified five new 5-HTR4b ligands: hordenine, halofuginone, proflavine, ethacridine, and revaprazan. We demonstrate that hordenine (antibiofilm), halofuginone (antiparasitic), and revaprazan (gastric acid reducer) activate 5-HTR4b in human colon epithelial cells, leading to increased cell motility or wound healing. The 5-HTR4b assay can be used to screen larger pharmaceutical libraries to identify novel treatments for IBS-C. This work shows that antimicrobials interact not only with the gut microbiota, but also with the human host. PMID: 31714751 [PubMed - as supplied by publisher] View the full article
  17. Stress and the brain-gut axis in functional and chronic-inflammatory gastrointestinal diseases: A transdisciplinary challenge. Psychoneuroendocrinology. 2019 Nov 02;111:104501 Authors: Labanski A, Langhorst J, Engler H, Elsenbruch S Abstract The broad role of stress in the brain-gut axis is widely acknowledged, with implications for multiple prevalent health conditions that are characterized by chronic gastrointestinal symptoms. These include the functional gastrointestinal disorders (FGID), such as irritable bowel syndrome and functional dyspepsia, as well as inflammatory bowel diseases (IBD) like ulcerative colitis and Crohn's disease. Although the afferent and efferent pathways linking the gut and the brain are modulated by stress, the fields of neurogastroenterology and psychoneuroendocrinology (PNE)/ psychoneuroimmunology (PNI) remain only loosely connected. We aim to contribute to bringing these fields closer together by drawing attention to a fascinating, evolving research area, targeting an audience with a strong interest in the role of stress in health and disease. To this end, this review introduces the concept of the brain-gut axis and its major pathways, and provides a brief introduction to epidemiological and clinical aspects of FGIDs and IBD. From an interdisciplinary PNE/PNI perspective, we then detail current knowledge regarding the role of chronic and acute stress in the pathophysiology of FGID and IBD. We provide an overview of evidence regarding non-pharmacological treatment approaches that target central or peripheral stress mechanisms, and conclude with future directions, particularly those arising from recent advances in the neurosciences and discoveries surrounding the gut microbiota. PMID: 31715444 [PubMed - as supplied by publisher] View the full article
  18. Related Articles Adherence to the pro-inflammatory diet in relation to prevalence of irritable bowel syndrome. Nutr J. 2019 Nov 11;18(1):72 Authors: Salari-Moghaddam A, Keshteli AH, Esmaillzadeh A, Adibi P Abstract OBJECTIVE: There is no prior study that examined the association between nutrient-based dietary inflammatory index (DII) and odds of Irritable Bowel Syndrome (IBS). We examined the association between DII score and odds of IBS and its severity among Iranian adults. METHODS: In this cross-sectional study, dietary intakes of 3363 Iranian adults were examined using a validated Dish-based 106-item Semi-quantitative Food Frequency Questionnaire (DS-FFQ). DII was calculated based on dietary intakes derived from DS-FFQ. IBS was assessed using a modified Persian version of Rome III questionnaire. RESULTS: After adjustment for potential confounders, we found that participants in the highest quintile of DII score had greater chance for IBS compared with those in the lowest quintile (OR: 1.36; 95% CI: 1.03-1.80). By gender, we found a significant association between DII score and IBS among women (OR: 1.41; 95% CI: 1.00-2.00). By BMI status, overweight or obese (BMI ≥ 25 kg/m2) individuals in top quintile of DII score had greater odds for IBS than those in the bottom quintile (OR: 1.64; 95% CI: 1.07-2.53). No significant association was observed between a pro-inflammatory diet and severity of IBS symptoms. CONCLUSIONS: Consumption of a pro-inflammatory diet was associated with increased odds of IBS, in particular among women and those with BMI ≥ 25 kg/m2. PMID: 31711479 [PubMed - in process] View the full article
  19. Gosport mum shares how bullies caused her IBS in the hope of preventing others being picked on Portsmouth NewsView the full article
  20. Bold Health Partners with the University of Pennsylvania for Clinical Trial of Its Zemedy IBS App PR.comView the full article
  21. RT @ea_haller: Reminder: Join me tomorrow! Excited to be discussing all things diet and IBD & answering all your questions LIVE: @CrohnsColitisFn Nov 13 at 5:00pm Join http://facebook.com/ccfafb (Feed generated with FetchRSS) View the full article
  22. RT @LaurenCornellRD: Many #foods can cause #foodborneillness if they are kept long past their prime. Be sure to check out some general guidelines for how long to store different food types from @foodsafetygov here: https://bit.ly/34OBZSk #HowToTuesday #foodsafety (Feed generated with FetchRSS) View the full article
  23. Jeffrey Roberts

    VIBERZi 75 with no gallbladder

    I'm so sorry for you. While I have heard of some patients working very closely with the doctor while taking Viberzi because they do not have a gallbladder, the FDA guidelines clearly state that Viberzi should not be used for anyone without a gallbladder. There is a very great risk of Sphincter of Oddi spasm causing temporary back-up of biliary and pancreatic juices, resulting in attacks of abdominal pain. This is not a minor issue and could result in hospitalization or worse. I don't know what else to suggest other than Lotronex or Xifaxin. Xifaxin is not a permanent solution whereas Lotronex might be. Did your gastro doctor make a recommendation?
  24. Linda Schafer

    VIBERZi 75 with no gallbladder

    My gastro is now telling me not to take VIBERZi. I take the 75 mg. Cause I have no gallbladder. It works like a miracle drug for me. I want my life and VIBERZi gives it to me. I am 71 and tired of fighting ibsd. I also take miralax so I don’t get constipated. Someone please give me some good news.
  25. VIDEO: Human milk oligosaccharides effective in IBS HealioView the full article
  26. summergirl24

    IBS - who can relate

    Hello all. I’m 25 years old, I’ve had IBS since I was about 18. I’ve tried so many different remedies and I currently take Linzess, but nothing is helping and I feel it’s getting worse. Luckily I am going to see a GI specialist soon. I rarely have diarrhea, constipation sticks with me. Sometimes it feels like there are vibrations going through my abdomen. It’s super uncomfortable and loud. I drink tons of water and recently started drinking green tea. I’m very active at work and I try to keep a consistent exercise schedule although sometimes the IBS has me feeling so awful I just lay down because that makes me feel better. I eat fiber that doesn’t work seems to make it worse. I’m honestly afraid to eat anything. With the holidays coming up I’m already thinking I’ll be staying home because I don’t want to be in an uncomfortable situation from my IBS. What are your symptoms? What works for you? Sent from my iPhone using Tapatalk
  27. Stress and constipation: What is the link? Medical News TodayView the full article
  1. Load more activity
Advertisement


×
×
  • Create New...